Does subsidy work? Price elasticity of demand for influenza vaccination among the elderly in Japan

Kondo, Masahide; Hoshi, Shu-ling; Okubo, Ichiro

doi:10.1016/j.healthpol.2008.12.014

Cited by 16 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies focused on the elderly, of which four evaluated the cost-effectiveness of seasonal influenza vaccination for the elderly [119]–[122], two assessed the cost-effectiveness of combining influenza and pneumococcal vaccination compared to influenza vaccination alone [120], [123], and two assessed the impact of subsidizing the cost of vaccination [124], [125]. One study from Hong Kong (China) assessed the cost-effectiveness of vaccine including subsidy in the general population [126].…”

Section: Resultsmentioning

confidence: 99%

A Review of the Evidence to Support Influenza Vaccine Introduction in Countries and Areas of WHO's Western Pacific Region

2013

View full text Add to dashboard Cite

BackgroundImmunization against influenza is considered an essential public health intervention to control both seasonal epidemics and pandemic influenza. According to the World Health Organization (WHO), there are five key policy and three key programmatic issues that decision-makers should consider before introducing a vaccine. These are (a) public health priority, (b) disease burden, (c) efficacy, quality and safety of the vaccine, (d) other inventions, (e) economic and financial issues, (f) vaccine presentation, (g) supply availability and (h) programmatic strength. We analyzed the body of evidence currently available on these eight issues in the WHO Western Pacific Region.Methodology/Principal FindingsStudies indexed in PubMed and published in English between 1 January 2000 and 31 December 2010 from the 37 countries and areas of the Western Pacific Region were screened for keywords pertaining to the five policy and three programmatic issues. Studies were grouped according to country income level and vaccine target group. There were 133 articles that met the selection criteria, with most (90%) coming from high-income countries. Disease burden (n = 34), vaccine efficacy, quality and safety (n = 27) and public health priority (n = 27) were most frequently addressed by studies conducted in the Region. Many studies assessed influenza vaccine policy and programmatic issues in the general population (42%), in the elderly (24%) and in children (17%). Few studies (2%) addressed the eight issues relating to pregnant women.Conclusions/SignificanceThe evidence for vaccine introduction in countries and areas in this Region remains limited, particularly in low- and middle-income countries that do not currently have influenza vaccination programmes. Surveillance activities and specialized studies can be used to assess the eight issues including disease burden among vaccine target groups and the cost-effectiveness of influenza vaccine. Multi-country studies should be considered to maximize resource utilization for cross-cutting issues such as vaccine presentation and other inventions.

show abstract

Section: Resultsmentioning

confidence: 99%

A Review of the Evidence to Support Influenza Vaccine Introduction in Countries and Areas of WHO's Western Pacific Region

2013

View full text Add to dashboard Cite

show abstract

“…9 These estimates are for overall medical expenditure, and much research has focused on components of medical expenditures. To give some sense of the breadth of research available, see Goldman, Joyce, and Zheng (2007) for a survey of price-elasticity of demand for prescription drugs; Kondo, Hoshi, and Okubo (2009) for a study on the elasticity of demand for vaccinations ;Connolly, Griesinger, Ledger, and Postma (2009) for research on the elasticity of demand for Assisted Reproductive Technologies (ART).…”

Section: Moral Hazardmentioning

confidence: 99%

Economic Analysis of Risk and Uncertainty Induced by Health Shocks: A Review and Extension

Philipson¹,

Zanjani²

2014

Handbook of the Economics of Risk and Uncertainty

View full text Add to dashboard Cite

This paper is a forthcoming chapter in the North Holland Handbook series "Handbook of Economics of Risk and Uncertainty" edited by Mark Machina and Kip Viscusi. We are thankful to the editors for comments that improved the chapter. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. NBER working papers are circulated for discussion and comment purposes. They have not been peerreviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

show abstract

“…After that, Zhang et al [37] demonstrated that the hubs may largely inhibit the outbreaks of infectious diseases under the voluntary vaccination policy. In the meantime, various subsidy policies on controlling the epidemic spreading have been determined from the socioeconomic perspectives within the well-mixed and networked population [38][39][40][41][42][43] . Furthermore, most previous works [44][45][46][47][48][49][50][51][52] often assume that the vaccine has a perfect efficacy, which will endow the complete immunity for the inoculated individuals, but an interesting topic is on how the epidemic spreads when the vaccine is not fully effective for the disease (i.e., 100% efficacy)?…”

Section: Introductionmentioning

confidence: 99%

Role of vaccine efficacy in the vaccination behavior under myopic update rule on complex networks

Huang

Wang

Xia

2020

Chaos, Solitons & Fractals

View full text Add to dashboard Cite

a b s t r a c tHow to effectively prevent the diffusion of infectious disease has become an intriguing topic in the field of public hygienics. To be noted that, for the non-periodic infectious diseases, many people hope to obtain the vaccine of epidemics in time to be inoculated, rather than at the end of the epidemic. However, the vaccine may fail as a result of invalid storage, transportation and usage, and then vaccinated individuals may become re-susceptible and be infected again during the outbreak. To this end, we build a new framework that considers the imperfect vaccination during the one cycle of infectious disease within the spatially structured and heterogeneous population. Meanwhile, we propose a new vaccination update rule: myopic update rule, which is only based on one focal player's own perception regarding the disease outbreak, and one susceptible individual makes a decision to adopt the vaccine just by comparing the perceived payoffs vaccination with the perceived ones of being infected. Extensive Monte-Carlo simulations are performed to demonstrate the imperfect vaccination behavior under the myopic update rule in the spatially structured and heterogeneous population. The results indicate that healthy individuals are often willing to inoculate the vaccine under the myopic update rule, which can stop the infectious disease from being spread, in particular, it is found that the vaccine efficacy influences the fraction of vaccinated individuals much more than the relative cost of vaccination on the regular lattice, Meanwhile, vaccine efficacy is more sensitive on the heterogeneous scale-free network. Current results are helpful to further analyze and model the choice of vaccination strategy during the disease outbreaks.

show abstract

Does subsidy work? Price elasticity of demand for influenza vaccination among the elderly in Japan

Cited by 16 publications

References 18 publications

A Review of the Evidence to Support Influenza Vaccine Introduction in Countries and Areas of WHO's Western Pacific Region

A Review of the Evidence to Support Influenza Vaccine Introduction in Countries and Areas of WHO's Western Pacific Region

Economic Analysis of Risk and Uncertainty Induced by Health Shocks: A Review and Extension

Role of vaccine efficacy in the vaccination behavior under myopic update rule on complex networks

Contact Info

Product

Resources

About